PPGN Stock Analysis: PolyPeptide | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 1.518m CHF | 12M Return: 114.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.35M
Warnings
Tailwinds
Seasonality 5.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
PolyPeptide Group AG (PPGN) is a Swiss-based contract development and manufacturing organization (CDMO) specializing in synthetic peptides used as active pharmaceutical ingredients (APIs) and intermediates in therapeutic products. Founded in 1952 and headquartered in Baar, Switzerland, the company operates across Europe, the United States, and Asia Pacific, serving academic, pharmaceutical, and biotech clients.
The companys product portfolio includes peptides targeting metabolic diseases such as GLP-1 receptor agonists, alongside generic peptides and peptide applications in cosmetics, animal health, and medical devices. It also offers development and analytical services. PolyPeptide is a subsidiary of Draupnir Holding B.V.
As a CDMO, PolyPeptide generates revenue through fee-for-service contracts and custom manufacturing agreements rather than selling its own branded drugs, which positions it as a supplier benefiting from third-party demand for peptide-based therapies. The peptide CDMO sector has drawn increased attention due to growing global demand for GLP-1-based treatments for diabetes and obesity.
- GLP-1 peptide API demand surge accelerates revenue growth
- New manufacturing capacity expansion supports contract pipeline
- Customer concentration risk with major GLP-1 drug developers
| Net Income: -21.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -4.15 > 1.0 |
| NWC/Revenue: 35.47% < 20% (prev 39.70%; Δ -4.23% < -1%) |
| CFO/TA 0.09 > 3% & CFO 77.1m > Net Income -21.2m |
| Net Debt (76.9m) to EBITDA (44.7m): 1.72 < 3 |
| Current Ratio: 1.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.0m) vs 12m ago 0.06% < -2% |
| Gross Margin: 16.44% > 18% (prev 11.13%; Δ 5.31% > 0.5%) |
| Asset Turnover: 49.27% > 50% (prev 44.52%; Δ 4.75% > 0%) |
| Interest Coverage Ratio: 0.22 > 6 (EBIT TTM 6.60m / Interest Expense TTM 30.1m) |
| A: 0.17 (Total Current Assets 324.6m - Total Current Liabilities 186.4m) / Total Assets 825.3m |
| B: 0.15 (Retained Earnings 122.5m / Total Assets 825.3m) |
| C: 0.01 (EBIT TTM 6.60m / Avg Total Assets 790.9m) |
| D: 0.70 (Book Value of Equity 340.3m / Total Liabilities 485.0m) |
| Altman-Z'' = 2.38 = BBB |
| DSRI: 0.88 (Receivables 88.0m/86.3m, Revenue 389.7m/336.8m) |
| GMI: 0.68 (GM 11.13% / 16.44%) |
| AQI: 0.98 (AQ_t 0.05 / AQ_t-1 0.05) |
| SGI: 1.16 (Revenue 389.7m / 336.8m) |
| TATA: -0.12 (NI -21.2m - CFO 77.1m) / TA 825.3m) |
| Beneish M = -3.33 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at CHF 45.70 with a total of 32,412 shares traded. Over the past week, the price has changed by -7.40%, over one month by +35.81%, over three months by +27.30% and over the past year by +114.05%.
Current recommended Stop Loss: 43.20 (which is 5.5% or 1.2 ATR below the current price).
PolyPeptide has no consensus analysts rating.
Market Cap EUR = 1.64b (1.52b CHF * 1.0825 CHF.EUR)
P/E Forward = 73.5294
P/S = 3.8998
P/B = 4.8371
Revenue TTM = 389.7m EUR
EBIT TTM = 6.60m EUR
EBITDA TTM = 44.7m EUR
Long Term Debt = 109.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 5.55m EUR (from shortTermDebt, last quarter)
Debt = 151.5m EUR (from shortLongTermDebtTotal, last quarter) + Leases 21.0m
Net Debt = 76.9m EUR (calculated: Debt 151.5m - CCE 74.6m)
Enterprise Value = 1.72b EUR (1.64b + Debt 151.5m - CCE 74.6m)
Interest Coverage Ratio = 0.22 (Ebit TTM 6.60m / Interest Expense TTM 30.1m)
EV/FCF = -56.77x (Enterprise Value 1.72b / FCF TTM -30.3m)
FCF Yield = -1.76% (FCF TTM -30.3m / Enterprise Value 1.72b)
FCF Margin = -7.78% (FCF TTM -30.3m / Revenue TTM 389.7m)
Net Margin = -5.43% (Net Income TTM -21.2m / Revenue TTM 389.7m)
Gross Margin = 16.44% ((Revenue TTM 389.7m - Cost of Revenue TTM 325.6m) / Revenue TTM)
Gross Margin QoQ = 22.59% (prev 8.25%)
Tobins Q-Ratio = 2.08 (Enterprise Value 1.72b / Total Assets 825.3m)
Interest Expense / Debt = 19.89% (Interest Expense 30.1m / Debt 151.5m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = 4.95m (EBIT 6.60m * (1 - 25.00%))
Current Ratio = 1.74 (Total Current Assets 324.6m / Total Current Liabilities 186.4m)
Debt / Equity = 0.45 (Debt 151.5m / totalStockholderEquity, last quarter 340.3m)
Debt / EBITDA = 1.72 (Net Debt 76.9m / EBITDA 44.7m)
Debt / FCF = -2.54 (negative FCF - burning cash) (Net Debt 76.9m / FCF TTM -30.3m)
Total Stockholder Equity = 347.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.68% (Net Income -21.2m / Total Assets 825.3m)
RoE = -6.10% (Net Income TTM -21.2m / Total Stockholder Equity 347.1m)
RoCE = 1.45% (EBIT 6.60m / Capital Employed (Equity 347.1m + L.T.Debt 109.0m))
RoIC = 0.79% (NOPAT 4.95m / Invested Capital 625.0m)
WACC = 11.35% (E(1.64b)/V(1.80b) * Re(11.02%) + D(151.5m)/V(1.80b) * Rd(19.89%) * (1-Tc(0.25)))
Discount Rate = 11.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 20.13 | Cagr: -0.10%
[DCF] Fair Price = unknown (Cash Flow -30.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 85.81 | Revenue CAGR: 23.82% | SUE: 0.02 | # QB: 0
EPS current Year (2026-12-31): EPS=0.80 | Chg30d=+27.92% | Revisions=+57% | GrowthEPS=+224.9% | GrowthRev=+25.5%
EPS next Year (2027-12-31): EPS=1.42 | Chg30d=+14.81% | Revisions=+57% | GrowthEPS=+77.5% | GrowthRev=+15.4%
[Analyst] Revisions Ratio: +73% (up=8, down=0)